PERSPECTA

News from every angle

← Back to headlines

CRISPR Therapeutics Stock Dips on $350M Convertible Debt Offering

CRISPR Therapeutics' stock experienced a decline following the announcement of a $350 million convertible debt offering.

10 Mar, 11:07 — 10 Mar, 11:07
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed164d ago

CRISPR Therapeutics stock dips on $350M convertible debt offering

Read full article →

Related Stories

TikTok Settles US Child Privacy Case for $400 Million

31m ago

Moderna's Cancer Vaccine Breakthrough Boosts Biotech Hopes

57m ago

Iran Threatens Military Action Against US Sanctions

1h ago

Executives Sell Millions in Company Stock Across Multiple Firms

1h ago

CRISPR Therapeutics Stock Dips on $350M Convertible Debt Offering | Perspecta News